QCNW Liverpool has over 15 years’ experience in planning, performing and managing stability studies on monoclonal antibody (mAb) preparations both for the NHS and commercial pharma in the UK and worldwide.

Previous mAb studies have included:

-Bevacizumab, Trastuzumab (Herceptin and Biosimilar), Rituximab, Infliximab (Remicade and biosimilar), Ipilimumab, Ranibizumab, Pembrolizumab and Nivolumab.

Techniques used for mAb studies at QCNW include:

-pH, sub-visible particle counts, SEC-HPLC, reducing and non-reducing capillary gel electrophoresis, capillary zone electrophoresis and ELISA. Cell assay analysis delivered through specialist partner.